Indoco Remedies Ltd.

BSE: INDOCO532612ISIN INE873D01024

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹214.20-0.55 (-0.26%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹287.35
52W low: ₹163.70
Off 52W high: -25.46%
1M return: -13.28%
3M return: -3.88%
6M return: -6.03%
1Y return: -21.60%
20D avg volume: 15,657
50 DMA: ₹240.78
200 DMA: ₹222.16

Key ratios Consolidated

Market cap: ₹1,977 Cr
Current price: ₹214.20
52W high / low: ₹287.35 / ₹163.70
Face value: ₹2.00
P/E: 62.21
P/B: 1.94
EPS (TTM): ₹3.44
Book value / share: ₹110.68
ROE: —
ROCE: 1.00%
Operating margin: —
Net margin: —
Debt / equity: 1.11
Net debt: ₹1,010 Cr
Interest cover: 0.13
Dividend yield: 0.09%
Dividend / share (TTM): ₹0.20
Payout: 5.81%
Cash conversion cycle: 115.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	520.17	467.50	475.61	445.36	484.67	437.89	390.21	410.55	432.66	431.49	449.64	459.42
	1.97	2.18	0.04	0.98	0.76	1.63	2.02	0.85	1.56	1.03	2.66	2.35
	522.14	469.68	475.57	446.34	485.43	439.52	392.23	411.40	434.22	432.52	452.30	461.77
	535.09	489.30	504.31	471.50	498.43	476.18	437.75	443.35	439.06	425.55	439.05	430.94
	127.63	104.58	109.18	97.89	112.99	105.53	85.86	109.91	94.26	106.24	121.80	129.30
	55.79	39.89	32.52	32.99	38.82	39.23	30.62	34.93	39.15	36.23	27.17	30.62
	105.11	101.41	109.41	106.03	103.23	107.02	106.36	97.55	92.88	97.26	88.30	89.97
	26.91	28.29	45.92	25.64	24.56	26.12	17.98	16.11	17.83	14.31	12.05	10.07
	34.44	34.53	32.49	32.01	32.25	29.70	28.78	28.72	28.82	27.52	26.23	24.35
	188.79	167.02	175.48	187.40	193.05	178.37	178.66	168.39	147.46	120.28	148.25	140.06
	-12.95	-19.62	-28.74	-25.16	-13.00	-36.66	-45.52	-31.95	-4.84	6.97	13.25	30.83
	37.14	97.34	3.74	-6.15	-0.53	0.00	0.00	0.99	0.00	0.00	19.73	-8.20
	24.19	77.72	-25.00	-31.31	-13.53	-36.66	-45.52	-30.96	-4.84	6.97	32.98	22.63
	4.72	12.28	-1.32	-1.86	4.32	0.31	4.18	2.56	5.17	5.15	10.95	7.07
	19.47	65.44	-23.68	-29.45	-9.21	-36.35	-41.34	-28.40	-10.01	1.82	22.03	15.56
	2.11	7.09	-2.57	-3.20	-1.00	-3.94	-4.48	-3.08	-1.09	0.20	2.39	1.69
Key metrics
	85.54	140.54	53.41	26.34	43.28	19.16	1.24	13.87	41.81	48.80	71.26	57.05
	16.40%	30.10%	11.20%	5.90%	8.90%	4.40%	0.30%	3.40%	9.70%	11.30%	15.80%	12.40%
	3.70%	14.00%	-5.00%	-6.60%	-1.90%	-8.30%	-10.60%	-6.90%	-2.30%	0.40%	4.90%	3.40%
	3.10%	—	1.40%	—	0.70%	—	-1.70%	—	—	—	—	—
	7.30%	6.80%	21.90%	8.50%	12.00%	1.50%	-13.20%	-10.60%	—	—	—	—
	311.40%	280.00%	42.70%	-3.70%	8.00%	-2,097.30%	-287.70%	-282.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,909	1,845	1,665	1,817	1,669	1,541
	5.17	3.33	5.45	9.85	2.34	2.33
	1,914	1,849	1,670	1,827	1,671	1,543
	2,000	1,952	1,746	1,703	1,478	1,307
	439.28	425.60	396.27	485.01	412.02	393.66
	161.19	143.55	140.93	115.66	102.72	89.43
	421.96	425.69	394.05	361.93	322.58	293.70
	126.76	122.25	66.23	38.02	25.03	14.14
	133.47	126.45	113.84	91.87	70.61	78.96
	718.69	736.09	673.43	554.70	457.67	388.28
	-86.47	-103.57	-75.36	124.27	192.80	236.57
	132.07	-2.94	0.99	11.53	0.00	0.00
	45.60	-106.51	-74.37	135.80	192.80	236.57
	13.82	7.81	3.58	38.79	50.55	81.77
	31.78	-98.70	-77.95	97.01	142.25	154.80
	3.43	-10.70	8.46	10.53	15.44	16.80
Key metrics
	305.83	142.19	105.70	265.69	288.44	329.67
	16.02%	7.70%	6.30%	14.60%	17.30%	21.40%
	1.67%	-5.30%	-4.70%	5.30%	8.50%	10.00%
	—	1.00%	-0.50%	—	—	—
	10.75%	10.80%	-8.40%	8.90%	8.30%	—
	—	-26.60%	-180.40%	-31.80%	-8.10%	—
	—	44.70	-261.22	—	—	—
	—	-1.95	-1.22	—	—	—
	—	1.11	0.98	—	—	—
	—	1,010	981.46	—	—	—
	—	115.9	123.6	—	—	—
Balance sheet
	—	2,593	2,430	—	—	—
	—	1,193	1,001	—	—	—
	—	25.93	12.10	—	—	—
	—	489.17	352.41	—	—	—
	—	405.21	419.35	—	—	—
	—	226.92	187.45	—	—	—
	—	969.83	849.06	—	—	—
	—	308.52	208.13	—	—	—
	—	1,053	807.99	—	—	—
	—	1,036	993.56	—	—	—
	—	519.83	451.00	—	—	—
	—	516.02	542.56	—	—	—
	—	932.11	1,018	—	—	—
Cash flow
	—	192.23	94.93	—	—	—
	—	-101.61	-339.11	—	—	—
	—	-76.80	241.42	—	—	—
	—	147.53	356.15	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	451.59	408.97	449.13	400.51	442.12	392.53	347.25	372.98	396.53	401.43	445.49	449.05
	5.02	4.47	10.35	7.17	6.54	5.58	6.50	4.26	4.20	3.52	4.05	2.93
	456.61	413.44	459.48	407.68	448.66	398.11	353.75	377.24	400.73	404.95	449.54	451.98
	459.05	417.56	435.54	422.12	438.37	426.51	384.65	391.59	383.35	385.44	422.77	416.76
	110.03	85.99	98.25	81.19	86.02	87.77	72.22	91.54	80.38	90.65	107.88	115.21
	55.80	39.59	29.08	32.99	38.82	39.23	30.62	34.94	39.14	36.23	27.17	30.62
	94.56	90.65	100.98	98.81	95.34	98.50	99.94	90.72	87.30	90.78	82.87	87.34
	19.87	22.75	22.73	20.15	22.01	23.61	15.98	14.00	14.77	11.88	10.91	10.03
	27.86	28.05	26.71	27.36	27.63	25.20	24.88	24.75	24.92	23.70	23.73	22.97
	161.03	135.66	147.21	163.21	164.51	158.03	153.99	139.24	123.04	102.84	140.49	136.04
	-2.44	-4.12	23.94	-14.44	10.29	-28.40	-30.90	-14.35	17.38	19.51	26.77	35.22
	37.14	97.34	3.68	-6.01	-0.53	0.00	0.00	0.99	—	—	19.73	-8.20
	34.70	93.22	27.62	-20.45	9.76	-28.40	-30.90	-13.36	17.38	19.51	46.50	27.02
	4.07	10.90	0.27	0.45	-5.29	0.34	-4.66	3.13	4.59	4.56	8.94	7.01
	30.63	82.32	27.35	-20.00	15.05	-28.06	-26.24	-10.23	12.79	14.95	37.56	20.01
	3.32	8.92	2.96	-2.17	1.63	-3.04	-2.85	-1.11	1.39	1.62	4.08	2.17
Key metrics
	82.43	144.02	77.06	27.06	59.40	20.41	9.96	25.39	57.07	55.09	81.14	60.02
	18.30%	35.20%	17.20%	6.80%	13.40%	5.20%	2.90%	6.80%	14.40%	13.70%	18.20%	13.40%
	6.80%	20.10%	6.10%	-5.00%	3.40%	-7.10%	-7.60%	-2.70%	3.20%	3.70%	8.40%	4.50%
	3.40%	—	3.40%	—	2.10%	—	-1.00%	—	—	—	—	—
	2.10%	4.20%	29.30%	7.40%	11.50%	-2.20%	-22.10%	-16.90%	—	—	—	—
	103.50%	393.40%	204.20%	-95.50%	17.70%	-287.70%	-169.90%	-151.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,710	1,686	1,518	1,791	1,667	1,540
	27.01	29.64	18.48	8.51	2.33	2.32
	1,737	1,716	1,537	1,799	1,669	1,542
	1,734	1,724	1,545	1,658	1,477	1,306
	375.46	353.23	334.79	445.50	412.02	393.62
	157.46	140.12	140.93	115.66	102.72	89.43
	385.00	393.63	368.74	350.55	321.15	292.41
	85.50	88.50	56.63	36.82	25.03	14.14
	109.98	106.90	98.25	87.98	70.60	78.95
	607.11	634.74	577.73	538.66	458.39	388.92
	2.94	-8.61	-8.36	141.69	191.59	236.23
	132.15	-2.86	0.99	11.53	—	—
	135.09	-11.47	-7.37	153.22	191.59	236.23
	15.69	-5.81	1.36	36.58	50.23	81.71
	120.30	-5.66	-8.73	116.64	141.36	154.52
	13.03	-0.61	-0.95	12.66	15.34	16.77
Key metrics
	330.57	183.93	147.51	278.02	287.22	329.32
	19.33%	10.90%	9.70%	15.50%	17.20%	21.40%
	7.03%	-0.30%	-0.60%	6.50%	8.50%	10.00%
	—	5.20%	3.30%	—	—	—
	9.99%	11.10%	-15.20%	7.40%	8.20%	—
	—	35.20%	-107.50%	-17.50%	-8.50%	—
	—	101.00	-167.66	—	—	—
	—	-39.99	-10.40	—	—	—
	—	0.64	0.68	—	—	—
	—	692.66	746.46	—	—	—
	—	130.5	141.7	—	—	—
Balance sheet
	—	2,365	2,201	—	—	—
	—	1,114	955.47	—	—	—
	—	12.94	7.06	—	—	—
	—	541.20	374.05	—	—	—
	—	321.83	362.87	—	—	—
	—	169.18	140.51	—	—	—
	—	703.46	670.62	—	—	—
	—	260.55	147.38	—	—	—
	—	875.47	695.01	—	—	—
	—	705.60	753.52	—	—	—
	—	403.99	407.27	—	—	—
	—	301.61	346.25	—	—	—
	—	1,099	1,103	—	—	—
Cash flow
	—	226.35	90.77	—	—	—
	—	-87.38	-259.79	—	—	—
	—	-133.09	168.62	—	—	—
	—	125.35	258.43	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +0.39%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +9.99%
Profit YoY (TTM): +343.13%

Consolidated

Sales CAGR 3Y: +3.41%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +10.75%
Profit YoY (TTM): +127.56%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 58.93%

Quarter	September 2026	June 2026
Promoter %	58.93%	58.87%

Holder	Type	Holding	Previous	Change
SPA HOLDINGS PVT LTD	Promoter Group	19.86%	19.86%	0.00%
SHANTERI INVESTMENT PVT LTD	Promoter	17.18%	17.18%	0.00%
KARE FAMILY PRIVATE TRUST	Promoter	14.19%	14.19%	0.00%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	Public	4.63%	4.80%	-0.17%
Quant Mutual Fund - Quant Small Cap Fund	Public	4.55%	4.55%	0.00%
Dsp Healthcare Fund	Public	4.34%	4.34%	0.00%
PANANDIKAR ADITI MILIND	Promoter	3.17%	3.16%	+0.01%
Madhura Suresh Kare	Promoter	2.70%	2.69%	+0.01%
Hdfc Value Fund	Public	1.66%	1.66%	0.00%
Kare Suresh Govind	Promoter	1.42%	1.40%	+0.02%
Mangeshi Investment Private Limited	Public	1.26%	1.26%	0.00%
Icici Prudential Healthcare Fund	Public	1.25%	—	—
SURESH GOVIND KARE HUF (Karta- Suresh Govind Kare)	Promoter	0.30%	0.30%	0.00%
SHARDA RAMNATH KARE	Promoter Group	0.04%	0.04%	0.00%
PRATIMA AJIT VAIDYA	Promoter Group	0.03%	0.03%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,37,952	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,69,451	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,449	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,26,703	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,19,341	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,13,578	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,243	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,03,881	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	1,02,895	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	90,887	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,147	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	61,956	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Biocon Ltd.	58,897	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Abbott India Ltd. S	56,508	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Gland Pharma Limited	51,934	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	49,458	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
Emcure Pharmaceuticals Limited	42,498	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
GlaxoSmithkline Pharmaceuticals Ltd.	42,363	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,012	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	33,915	1,546.30	90.80	18.10%	—	—	+67.49%
Wockhardt Ltd	32,340	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
PIRAMAL PHARMA LIMITED	31,793	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,838	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
RUBICON RESEARCH LIMITED	28,809	1,716.55	98.59	24.30%	—	—	+164.06%
Indoco Remedies Ltd.	1,980	214.20	62.21	1.00%	+10.75% TTM	+127.56% TTM	-21.60%

Filings & corporate actions

Recent announcements

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ms. Aditi M Panandikar & Ms. Madhura Suresh Kare4 Nov 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others3 Nov 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-09-202629 Oct 2026 · Company Update / Earnings Call Transcript
Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter & half year ended 30-09-202628 Oct 2026 · Company Update / Newspaper Publication
Audio recording of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 202627 Oct 2026 · Company Update / Analyst / Investor Meet
Indoco''s Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities27 Oct 2026 · Company Update / Press Release / Media Release
Approval of the Financial Results for the Quarter and Half Year Ended 30th September, 202627 Oct 2026 · Result / Financial Results
Pursuant to the Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we hereby inform you that the Board ....27 Oct 2026 · Board Meeting / Outcome of Board Meeting
Pursuant to Regulation 30 of SEBI LODR, this is to inform you that the Nomination and Remuneration Committee in its meeting held today i.e. 27th October, 2026 has approved the allotment ....27 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter and Half year ended 30th September 202621 Oct 2026 · Company Update / Analyst / Investor Meet
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve A meeting of the Board of Directors ....14 Oct 2026 · Board Meeting / Board Meeting
Attached the certificate issued by MUFG Intime India Private Ltd, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI(D & P) Regulations,2018 ....7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (LODR) Regulations,2015, please find enclosed a copy of the letter dispatched to shareholders holding shares in physical mode, ....29 Sep 2026 · Company Update / General
Pursuant to Regulation 30 of the SEBI (LODR) Regulations,2015, please note that the Company received intimation today that the Wholly Owned Subsidiary of the Company in the name and style ....28 Sep 2026 · Company Update / Acquisition
Intimation regarding Closure of Trading Window28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015-ESG rating24 Sep 2026 · Company Update / General
Pursuant to Regulation 30 of SEBI LODR, the Committee of Executive Directors in its meeting held today i.e. 18th September, 2026 has considered and approved the incorporation of the wholly ....18 Sep 2026 · Company Update / Acquisition
Please find enclosed herewith the details of Voting Results and Scrutinizers Report for the 79th AGM of the Company held on 17th September, 202618 Sep 2026 · AGM/EGM / AGM
We are submitting herewith the details regarding the Proceedings of the 79th AGM of the Company held on Thursday, 17th September, 2026 at 10.30 am through video conferencing(VC)/other audio ....17 Sep 2026 · AGM/EGM / AGM
UK MHRA inspection at Company''s manufacturing facility at Plant I (solid oral dosage form) located at Goa.10 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others10 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
USFDA inspection at Company''s manufacturing facility at Plant II (Sterile) located at Goa.5 Sep 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi Panandikar & Others3 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others1 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Intimation of execution of Deed of Conveyance for Sale of Company''s plot of land.27 Aug 2026 · Company Update / Memorandum of Understanding /Agreements
Newspaper Advertisement-Information regarding 79th Annual General meeting and E-voting22 Aug 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Reporting (BRSR)21 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the financial year 2025-202621 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of 79th Annual General Meeting and Annual Report for the Financial year 2025-202621 Aug 2026 · AGM/EGM / AGM
Notice of 79th Annual General Meeting and Annual Report for the financial year 2025-202621 Aug 2026 · AGM/EGM / AGM
Intimation of Cut-Off Date for E voting, Book Closure and Record date for Dividend21 Aug 2026 · Corp. Action / Record Date
Publication of Newspaper Advertisement- 79th Annual General Meeting to be held on 17th September, 2026 through VC/OAVM20 Aug 2026 · Company Update / Newspaper Publication
Transcript of Earnings Conference Call on Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30-06-20264 Aug 2026 · Company Update / Earnings Call Transcript
Publication of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30-06-202629 Jul 2026 · Company Update / Newspaper Publication
Audio recording of Earnings Conference Call on Unaudited Standalone & Consolidated Financial Results for the quarter ended 30-06-202628 Jul 2026 · Company Update / Analyst / Investor Meet
The Board of Directors in its Meeting held today i.e. 28th July, 2026 has considered and approved 1. Re-appointment of Ms. Aditi Panandikar as the Managing Director of the Company for ....28 Jul 2026 · Company Update / Change in Management
Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30th June, 2026 along with Limited Review Report28 Jul 2026 · Result / Financial Results
Pursuant to the Regulation 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors ....28 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Earnings Conference Call on Unaudited Financial Results for Quarter ended 30th June, 202617 Jul 2026 · Company Update / Analyst / Investor Meet
Indoco Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve The Unaudited Standalone and ....15 Jul 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.2000	10 Sep 2026	10 Sep 2026	—
Final Dividend - Rs. - 0.2000	4 Sep 2025	4 Sep 2025	—
Final Dividend - Rs. - 1.5000	19 Sep 2024	—	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
28 Jul 2026 Board Meeting - Financial Results